We are live on ! Find out more
Forefront Analytics

Forefront Analytics Portfolio holdings

AUM $97M Turnover 5.13%
1-Year Est. Return 18.05%
This Fund
S&P 500
This Quarter Est. Return
+1.25%
1 Year Est. Return
+18.05%
3 Year Est. Return
+59.65%
5 Year Est. Return
+37.83%
10 Year Est. Return
–
AUM
$175M
AUM Growth
-$18.7M
Cap. Flow
-$20.4M
Cap. Flow %
-11.66%
Top 10 Hldgs %
62.95%
Holding
80
New
1
Increased
22
Reduced
41
Closed
15
Avg Time Held
3.3 years
Top 10 Avg Time Held
2.2 years
Top 20 Avg Time Held
3.7 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 97.74%
2 Healthcare 1.3%
3 Technology 0.42%
4 Financials 0.29%
5 Industrials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
REGN icon
51
Regeneron Pharmaceuticals
REGN
$95.2B
$245K 0.14%
341
-16
-4% -$12.3K
2022 Q3
3 quarters
TMO icon
52
Thermo Fisher Scientific
TMO
$248B
$223K 0.13%
427
-48
-10% -$25.9K
2023 Q1
1 quarter
INCY icon
53
Incyte
INCY
$23.4B
$220K 0.13%
3,533
+8
+0.2% +$535
2022 Q4
2 quarters
MDT icon
54
Medtronic
MDT
$128B
$214K 0.12%
2,431
-853
-26% -$73.4K
2022 Q4
2 quarters
MREO icon
55
Mereo BioPharma
MREO
$41.5M
$109K 0.06%
82,749
-951
-1% -$1.1K
2022 Q2
4 quarters
JSPR icon
56
Jasper Therapeutics
JSPR
$9.6M
$95K 0.05%
231
+130
+129% +$57.9K
2022 Q1
5 quarters
ANNX icon
57
Annexon
ANNX
$591M
$94.3K 0.05%
26,790
+11,539
+76% +$50.4K
2022 Q1
5 quarters
FUSN icon
58
DELISTED
Fusion Pharmaceuticals
FUSN
$93.8K 0.05%
+20,075
New +$86.8K
2023 Q2
0 quarters
CTMX icon
59
CytomX Therapeutics
CTMX
$443M
$85.3K 0.05%
49,596
+23,184
+88% +$38.5K
2021 Q3
7 quarters
ACHL
60
DELISTED
Achilles Therapeutics
ACHL
$70.7K 0.04%
74,769
-856
-1% -$813
2022 Q3
3 quarters
KRON icon
61
DELISTED
Kronos Bio
KRON
$67.2K 0.04%
39,068
-227
-0.6% -$360
2023 Q1
1 quarter
LONA icon
62
LeonaBio
LONA
$26.4M
$61.4K 0.04%
2,081
-82
-4% -$2.34K
2022 Q4
2 quarters
GERN icon
63
Geron
GERN
$561M
$47.8K 0.03%
14,891
-12,691
-46% -$36.1K
2020 Q3
11 quarters
PSTX icon
64
DELISTED
Poseida Therapeutics
PSTX
$46.8K 0.03%
26,619
+11,579
+77% +$29.6K
2021 Q3
7 quarters
NKTX icon
65
Nkarta
NKTX
$81.7M
$22.7K 0.01%
10,367
-108
-1% -$475
2023 Q1
1 quarter
ABT icon
66
Abbott
ABT
$178B
– –
-3,009
Closed -$305K –
ALXO icon
67
ALX Oncology
ALXO
$137M
– –
-13,037
Closed -$58.9K –
DBC icon
68
Invesco DB Commodity Index Tracking Fund
DBC
$1.75B
– –
-13,343
Closed -$317K –
DBA icon
69
Invesco DB Agriculture Fund
DBA
$1.22B
– –
-40,111
Closed -$819K –
EEM icon
70
iShares MSCI Emerging Markets ETF
EEM
$25B
– –
-7,748
Closed -$306K –
HYG icon
71
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$18B
– –
-2,948
Closed -$223K –
IAU icon
72
iShares Gold Trust
IAU
$52.3B
– –
-46,743
Closed -$1.75M –
NULV icon
73
Nuveen ESG Large-Cap Value ETF
NULV
$2.44B
– –
-187,045
Closed -$6.37M –
PHG icon
74
Philips
PHG
$28B
– –
-11,679
Closed -$184K –
XLE icon
75
State Street Energy Select Sector SPDR ETF
XLE
$39.7B
– –
-12,240
Closed -$507K –

Similar funds

Forefront Analytics's Q2 2023 Portfolio in Review

As of Q2 2023, Forefront Analytics held 80 positions worth $175M, down 9.6% from $194M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Forefront Analytics withdrew a net $20.4M in Q2 2023, closing 15 positions and reducing 41 holdings. Its most notable exit was Nuveen ESG Large-Cap Value ETF, an estimated $6.37M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 98% of assets, up from 98% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Forefront Analytics opened a new position in Fusion Pharmaceuticals worth $93.8K.

  • Forefront Analytics's largest Q2 2023 buy was Fusion Pharmaceuticals: 20,075 shares worth $93.8K.
  • Forefront Analytics added most to iShares ESG Aware MSCI EAFE ETF in Q2 2023, an estimated $5.7M increase.
  • Forefront Analytics's biggest Q2 2023 reduction was Xtrackers MSCI EAFE Hedged Equity ETF, cutting an estimated $1.6M.
  • Forefront Analytics fully exited Nuveen ESG Large-Cap Value ETF in Q2 2023, selling an estimated $6.37M.
  • Forefront Analytics's ten largest holdings make up 63% of its $175M portfolio in Q2 2023.
  • Forefront Analytics opened 1 new position and closed 15 in Q2 2023.
  • Forefront Analytics's portfolio value fell 9.6% quarter-over-quarter to $175M.

Based on Forefront Analytics's 13F filing for Q2 2023, filed 11 Aug 2023.